Abstract
The useof Alisat for the treatment of patients with ischemic heart disease prevents the development of undesirable proatherogenic effects of prolonged therapy with the nonselective β-adrenoblocker, obsidan. Combined treatment with Alisat and obsidan was not accompanied by a decrease in plasma levels of high-density lipoprotein cholesterol and apolipoprotein A-I, an increase in the contents of conjugated dienes and malonic dialdehyde, and a decrease in the activity of glutathione peroxidase. However, prolonged obsidan monotherapy led to these changes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
